Why the study?
Does M3-mAChR overexpression inhibit cardiac hypertrophy induced by angiotensin II in preclinical models?
Does M3-mAChR overexpression inhibit cardiac hypertrophy induced by angiotensin II in preclinical models?
Upregulation of M3-mAChR attenuates Ang II-induced cardiac hypertrophy, potentially via downregulation of AT1 receptors and inhibition of MAPK signaling.
Hypothesis-generating for M3-mAChR modulation in Ang II-driven hypertrophy; requires human studies before clinical consideration.
BACKGROUND: M₃ muscarinic acetylcholine receptor (M₃-mAChR) is stably expressed in the myocardium, but its pathophysiological role remains largely undefined. This study aimed to investigate the role of M₃-mAChR in cardiac hypertrophy induced by angiotensin II (Ang II) and elucidate the underlying mechanisms. METHODS: Cardiac-specific M₃-mAChR overexpression transgenic (TG) mice and rat H9c2 cardiomyoblasts with ectopic expression of M₃-mAChR were established. Models of cardiac hypertrophy were induced by transverse aortic constriction (TAC) or Ang II infusion in the mice in vivo, and by isoproterenol (ISO) or Ang II treatment of H9c2 cells in vitro. Cardiac hypertrophy was evaluated by electrocardiography (ECG) measurement, hemodynamic measurement and histological analysis. mRNA and protein expression were detected by real-time RT-PCR and Western blot analysis. RESULTS: M₃-mAChR was upregulated in hypertrophic heart, while M₂-mAChR expression did not change significantly. M₃-mAChR overexpression significantly attenuated the increased expression of atrial natriuretic peptide and β-myosin heavy chain induced by Ang II both in vivo and in vitro. In addition, M₃-mAChR overexpression downregulated AT1 receptor expression and inhibited the activation of MAPK signaling in the heart. CONCLUSION: The upregulation of M₃-mAChR during myocardial hypertrophy could relieve the hypertrophic response provoked by Ang II, and the mechanism may involve the inhibition of MAPK signaling through the downregulation of AT1 receptor.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: